Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour
This article was originally published in Scrip
Amgen has collaborated with Micromet on its BiTE novel oncology platform since last July and it obviously has liked what it has seen, and then in December it heard news of promising Phase II data with a Micromet molecule for acute lymphocytic leukaemia (ALL), a difficult to treat blood cancer. This has now culminated in Amgen’s announcement that it will acquire Micromet for $11 per share in cash, for a total of around $1.16 billion, a 33% premium over the company’s closing price of $8.28 just before the deal was announced.
You may also be interested in...
Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
TCR2 Raises $125m To Make T-Cell Therapies Available To More Cancer Patients
TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.
Interview: Amgen's BiTE Platform Becomes A Feast As More Molecules Enter The Clinic
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.